Omeros (OMER) Price/Sales Ratio: History & Chart

Omeros Corporation(OMER)

Biotechnology · Seattle, WA

$18.72-0.18 (-0.95%)

Delayed quote: Oct 6, 2026, 11:40 AM EDT

About Omeros Corporation

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.

Seattle, WA

175 employees

www.omeros.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Gregory A. Demopulos

View full financials

OMER PS Ratio Metrics

PS RATIO

35.26

PS RATIO AVG TTM

78.10

PS RATIO AVG 3Y

78.10

PS RATIO AVG 5Y

55.15

PS RATIO AVG 10Y

16.82

PS RATIO AVG 15Y

28.78

PS RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-54.85%

CURRENT VS 3Y AVG

-54.85%

CURRENT VS 5Y AVG

-36.06%

CURRENT VS 10Y AVG

+109.68%

CURRENT VS 15Y AVG

+22.53%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

4.17

median of 471 covered companies

CURRENT VS SECTOR MEDIAN

+745.56%

vs the sector median at left

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
Omeros Corporation (OMER)	$1.35B	35.26	78.10	78.10	55.15
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.37B	N/A	N/A	N/A	N/A
Alpha Tau Medical Ltd (DRTS)vs ›	$1.32B	N/A	N/A	N/A	N/A
The Pennant Group, Inc. (PNTG)vs ›	$1.42B	1.29	1.22	1.22	1.12
Inhibrx Biosciences Inc. (INBX)vs ›	$1.42B	N/A	865.07	1036.91	726.94
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.42B	N/A	N/A	N/A	N/A
Kardigan, Inc. (KARD)vs ›	$1.28B	N/A	N/A	N/A	N/A
AnaptysBio, Inc. (ANAB)vs ›	$1.44B	6.05	6.28	11.75	20.01
Ultragenyx Pharmaceutical Inc. (RARE)vs ›	$1.44B	2.01	3.96	6.31	7.98
ORIC Pharmaceuticals, Inc. (ORIC)vs ›	$1.25B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PS RATIO

TTM

Omeros Corporation (OMER)

$1.35B

35.26

78.10

55.15

Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›

$1.37B

N/A

Alpha Tau Medical Ltd (DRTS)vs ›

$1.32B

N/A

The Pennant Group, Inc. (PNTG)vs ›

$1.42B

1.29

1.22

1.12

Inhibrx Biosciences Inc. (INBX)vs ›

$1.42B

N/A

865.07

1036.91

726.94

Kailera Therapeutics, Inc. (KLRA)vs ›

$1.42B

N/A

Kardigan, Inc. (KARD)vs ›

$1.28B

N/A

AnaptysBio, Inc. (ANAB)vs ›

$1.44B

6.05

6.28

11.75

20.01

Ultragenyx Pharmaceutical Inc. (RARE)vs ›

$1.44B

2.01

3.96

6.31

7.98

ORIC Pharmaceuticals, Inc. (ORIC)vs ›

$1.25B

N/A

Revenue calculation and filing references
Fiscal period	Revenue	Source
Q3 FY2025Period ended 2025-09-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13
Q4 FY2025Period ended 2025-12-31	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31
Q1 FY2026Period ended 2026-03-31	$9,893,000	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13
Q2 FY2026Period ended 2026-06-30	$28,529,000	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-12
TTM revenue	$38,422,000

Fiscal period

Revenue

Source

Q3 FY2025Period ended 2025-09-30

Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13

Q4 FY2025Period ended 2025-12-31

Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31

Q1 FY2026Period ended 2026-03-31

$9,893,000

Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13

Q2 FY2026Period ended 2026-06-30

$28,529,000

Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-12

TTM revenue

$38,422,000

PS Ratio FAQ

What is the P/S ratio for Omeros Corporation (OMER)?

The P/S ratio for OMER stock is 35.26.

Is Omeros Corporation's P/S ratio high or low?

The P/S ratio of 35.26 is 36% below its estimated 5-year average of 55.15, near the low end of its estimated 5-year range (9.62–124.89).

What is the estimated TTM average P/S ratio for Omeros Corporation (OMER)?

The estimated TTM average P/S ratio for OMER stock is 78.10.

What is the estimated 3Y average P/S ratio for Omeros Corporation (OMER)?

The estimated 3Y average P/S ratio for OMER stock is 78.10.

What is the estimated 5Y average P/S ratio for Omeros Corporation (OMER)?

The estimated 5Y average P/S ratio for OMER stock is 55.15.

What is the estimated 10Y average P/S ratio for Omeros Corporation (OMER)?

The estimated 10Y average P/S ratio for OMER stock is 16.82.

What is the estimated 15Y average P/S ratio for Omeros Corporation (OMER)?

The estimated 15Y average P/S ratio for OMER stock is 28.78.

DATE	PS RATIO
2026-10-05	44.09
2026-10-02	43.41
2026-10-01	43.08
2026-09-30	44.41
2026-09-29	44.90
2026-09-28	45.32
2026-09-25	46.84
2026-09-24	46.96
2026-09-23	48.38
2026-09-22	49.10
2026-09-21	43.13
2026-09-18	41.68
2026-09-17	43.04
2026-09-16	40.45
2026-09-15	40.05
2026-09-14	40.73
2026-09-11	42.64
2026-09-10	43.36
2026-09-09	45.23
2026-09-08	44.60
2026-09-04	44.20
2026-09-03	44.58
2026-09-02	43.99
2026-09-01	43.74
2026-08-31	43.83
2026-08-28	43.41
2026-08-27	44.90
2026-08-26	42.50
2026-08-25	44.97
2026-08-24	45.07
2026-08-21	44.95
2026-08-20	43.46
2026-08-19	42.90
2026-08-18	40.10
2026-08-17	40.50
2026-08-14	40.10
2026-08-13	40.47
2026-08-12	124.89
2026-08-11	123.88
2026-08-10	124.07
2026-08-07	120.70
2026-08-06	119.78
2026-08-05	115.23
2026-08-04	117.87
2026-08-03	114.41
2026-07-31	107.85
2026-07-30	108.67
2026-07-29	106.30
2026-07-28	102.75
2026-07-27	103.30
2026-07-24	89.18
2026-07-23	93.64
2026-07-22	89.63
2026-07-21	86.81
2026-07-20	87.72
2026-07-17	88.27
2026-07-16	83.99
2026-07-15	94.46
2026-07-14	95.65
2026-07-13	91.18
2026-07-10	93.64
2026-07-09	93.55
2026-07-08	93.28
2026-07-07	94.10
2026-07-06	94.19
2026-07-02	84.53
2026-07-01	85.72
2026-06-30	86.63
2026-06-29	90.27
2026-06-26	78.98
2026-06-25	97.65
2026-06-24	96.37
2026-06-23	95.46
2026-06-22	94.10
2026-06-18	93.64
2026-06-17	87.81
2026-06-16	86.35
2026-06-15	84.99
2026-06-12	79.61
2026-06-11	92.73
2026-06-10	92.91
2026-06-09	90.82
2026-06-08	89.72
2026-06-05	89.18
2026-06-04	93.37
2026-06-03	92.55
2026-06-02	93.46
2026-06-01	97.65
2026-05-29	100.56
2026-05-28	101.57
2026-05-27	100.84
2026-05-26	106.12
2026-05-22	104.39
2026-05-21	108.94
2026-05-20	112.77
2026-05-19	109.04
2026-05-18	106.58
2026-05-15	111.59
2026-05-14	120.97
2022-03-01	41.74
2022-02-28	42.33
2022-02-25	42.27
2022-02-24	40.92
2022-02-23	37.98
2022-02-22	38.98
2022-02-18	41.69
2022-02-17	39.80
2022-02-16	41.22
2022-02-15	40.63
2022-02-14	36.69
2022-02-11	37.16
2022-02-10	37.86
2022-02-09	39.69
2022-02-08	36.22
2022-02-07	39.92
2022-02-04	36.92
2022-02-03	35.86
2022-02-02	35.98
2022-02-01	37.63
2022-01-31	35.28
2022-01-28	33.10
2022-01-27	31.51
2022-01-26	31.40
2022-01-25	31.75
2022-01-24	29.81
2022-01-21	31.16
2022-01-20	31.46
2022-01-19	30.34
2022-01-18	30.46
2022-01-14	33.92
2022-01-13	34.10
2022-01-12	35.92
2022-01-11	36.92
2022-01-10	37.04
2022-01-07	36.86
2022-01-06	36.81
2022-01-05	36.86
2022-01-04	40.57
2022-01-03	41.10
2021-12-31	37.81
2021-12-30	39.04
2021-12-29	39.69
2021-12-28	40.51
2021-12-27	42.80
2021-12-23	44.92
2021-12-22	44.27
2021-12-21	43.39
2021-12-20	45.51
2021-12-17	43.10
2021-12-16	41.51
2021-12-15	42.92
2021-12-14	41.74
2021-12-13	43.27
2021-12-10	44.51
2021-12-09	46.62
2021-12-08	47.86
2021-12-07	44.68
2021-12-06	40.22
2021-12-03	40.39
2021-12-02	43.04
2021-12-01	40.10
2021-11-30	42.33
2021-11-29	41.57
2021-11-26	43.68
2021-11-24	45.86
2021-11-23	45.27
2021-11-22	44.10
2021-11-19	46.33
2021-11-18	45.62
2021-11-17	46.21
2021-11-16	48.45
2021-11-15	48.74
2021-11-12	48.27
2021-11-11	48.15
2021-11-10	47.21
2021-11-09	12.31
2021-11-08	12.66
2021-11-05	12.82
2021-11-04	12.75
2021-11-03	12.65
2021-11-02	11.80
2021-11-01	11.68
2021-10-29	10.64
2021-10-28	10.90
2021-10-27	10.83
2021-10-26	10.81
2021-10-25	10.73
2021-10-22	11.02
2021-10-21	10.97
2021-10-20	10.86
2021-10-19	10.56
2021-10-18	9.62
2021-10-15	13.12
2021-10-14	13.12
2021-10-13	12.53
2021-10-12	12.09
2021-10-11	12.15
2021-10-08	11.37
2021-10-07	12.61
2021-10-06	12.24
2021-10-05	12.02
2021-10-04	12.36
2021-10-01	14.50
2021-09-30	23.41
2021-09-29	22.75
2021-09-28	23.41
2021-09-27	24.66
2021-09-24	26.96
2021-09-23	27.07
2021-09-22	26.89
2021-09-21	26.85
2021-09-20	26.48
2021-09-17	27.12
2021-09-16	26.75
2021-09-15	26.39
2021-09-14	26.43
2021-09-13	27.02
2021-09-10	26.53
2021-09-09	27.24
2021-09-08	26.26
2021-09-07	26.53
2021-09-03	26.73
2021-09-02	27.16
2021-09-01	27.16
2021-08-31	27.67
2021-08-30	26.63
2021-08-27	26.77
2021-08-26	26.29
2021-08-25	26.39
2021-08-24	25.99
2021-08-23	25.38
2021-08-20	25.07
2021-08-19	23.37
2021-08-18	24.66
2021-08-17	24.97
2021-08-16	24.92
2021-08-13	26.02
2021-08-12	25.90
2021-08-11	26.02
2021-08-10	25.31
2021-08-09	17.90
2021-08-06	18.09
2021-08-05	18.75
2021-08-04	17.86
2021-08-03	18.21
2021-08-02	18.45
2021-07-30	17.86
2021-07-29	18.22
2021-07-28	18.06
2021-07-27	17.61
2021-07-26	17.71
2021-07-23	17.48
2021-07-22	17.54
2021-07-21	17.70
2021-07-20	17.61
2021-07-19	17.04
2021-07-16	16.75
2021-07-15	17.04
2021-07-14	16.86
2021-07-13	17.58

DATE

PS RATIO

2026-10-05

44.09

2026-10-02

43.41

2026-10-01

43.08

2026-09-30

44.41

2026-09-29

44.90

2026-09-28

45.32

2026-09-25

46.84

2026-09-24

46.96

2026-09-23

48.38

2026-09-22

49.10

2026-09-21

43.13

2026-09-18

41.68

2026-09-17

43.04

2026-09-16

40.45

2026-09-15

40.05

2026-09-14

40.73

2026-09-11

42.64

2026-09-10

43.36

2026-09-09

45.23

2026-09-08

44.60

2026-09-04

44.20

2026-09-03

44.58

2026-09-02

43.99

2026-09-01

43.74

2026-08-31

43.83

2026-08-28

43.41

2026-08-27

44.90

2026-08-26

42.50

2026-08-25

44.97

2026-08-24

45.07

2026-08-21

44.95

2026-08-20

43.46

2026-08-19

42.90

2026-08-18

40.10

2026-08-17

40.50

2026-08-14

40.10

2026-08-13

40.47

2026-08-12

124.89

2026-08-11

123.88

2026-08-10

124.07

2026-08-07

120.70

2026-08-06

119.78

2026-08-05

115.23

2026-08-04

117.87

2026-08-03

114.41

2026-07-31

107.85

2026-07-30

108.67

2026-07-29

106.30

2026-07-28

102.75

2026-07-27

103.30

2026-07-24

89.18

2026-07-23

93.64

2026-07-22

89.63

2026-07-21

86.81

2026-07-20

87.72

2026-07-17

88.27

2026-07-16

83.99

2026-07-15

94.46

2026-07-14

95.65

2026-07-13

91.18

2026-07-10

93.64

2026-07-09

93.55

2026-07-08

93.28

2026-07-07

94.10

2026-07-06

94.19

2026-07-02

84.53

2026-07-01

85.72

2026-06-30

86.63

2026-06-29

90.27

2026-06-26

78.98

2026-06-25

97.65

2026-06-24

96.37

2026-06-23

95.46

2026-06-22

94.10

2026-06-18

93.64

2026-06-17

87.81

2026-06-16

86.35

2026-06-15

84.99

2026-06-12

79.61

2026-06-11

92.73

2026-06-10

92.91

2026-06-09

90.82

2026-06-08

89.72

2026-06-05

89.18

2026-06-04

93.37

2026-06-03

92.55

2026-06-02

93.46

2026-06-01

97.65

2026-05-29

100.56

2026-05-28

101.57

2026-05-27

100.84

2026-05-26

106.12

2026-05-22

104.39

2026-05-21

108.94

2026-05-20

112.77

2026-05-19

109.04

2026-05-18

106.58

2026-05-15

111.59

2026-05-14

120.97

2022-03-01

41.74

2022-02-28

42.33

2022-02-25

42.27

2022-02-24

40.92

2022-02-23

37.98

2022-02-22

38.98

2022-02-18

41.69

2022-02-17

39.80

2022-02-16

41.22

2022-02-15

40.63

2022-02-14

36.69

2022-02-11

37.16

2022-02-10

37.86

2022-02-09

39.69

2022-02-08

36.22

2022-02-07

39.92

2022-02-04

36.92

2022-02-03

35.86

2022-02-02

35.98

2022-02-01

37.63

2022-01-31

35.28

2022-01-28

33.10

2022-01-27

31.51

2022-01-26

31.40

2022-01-25

31.75

2022-01-24

29.81

2022-01-21

31.16

2022-01-20

31.46

2022-01-19

30.34

2022-01-18

30.46

2022-01-14

33.92

2022-01-13

34.10

2022-01-12

35.92

2022-01-11

36.92

2022-01-10

37.04

2022-01-07

36.86

2022-01-06

36.81

2022-01-05

36.86

2022-01-04

40.57

2022-01-03

41.10

2021-12-31

37.81

2021-12-30

39.04

2021-12-29

39.69

2021-12-28

40.51

2021-12-27

42.80

2021-12-23

44.92

2021-12-22

44.27

2021-12-21

43.39

2021-12-20

45.51

2021-12-17

43.10

2021-12-16

41.51

2021-12-15

42.92

2021-12-14

41.74

2021-12-13

43.27

2021-12-10

44.51

2021-12-09

46.62

2021-12-08

47.86

2021-12-07

44.68

2021-12-06

40.22

2021-12-03

40.39

2021-12-02

43.04

2021-12-01

40.10

2021-11-30

42.33

2021-11-29

41.57

2021-11-26

43.68

2021-11-24

45.86

2021-11-23

45.27

2021-11-22

44.10

2021-11-19

46.33

2021-11-18

45.62

2021-11-17

46.21

2021-11-16

48.45

2021-11-15

48.74

2021-11-12

48.27

2021-11-11

48.15

2021-11-10

47.21

2021-11-09

12.31

2021-11-08

12.66

2021-11-05

12.82

2021-11-04

12.75

2021-11-03

12.65

2021-11-02

11.80

2021-11-01

11.68

2021-10-29

10.64

2021-10-28

10.90

2021-10-27

10.83

2021-10-26

10.81

2021-10-25

10.73

2021-10-22

11.02

2021-10-21

10.97

2021-10-20

10.86

2021-10-19

10.56

2021-10-18

9.62

2021-10-15

13.12

2021-10-14

13.12

2021-10-13

12.53

2021-10-12

12.09

2021-10-11

12.15

2021-10-08

11.37

2021-10-07

12.61

2021-10-06

12.24

2021-10-05

12.02

2021-10-04

12.36

2021-10-01

14.50

2021-09-30

23.41

2021-09-29

22.75

2021-09-28

23.41

2021-09-27

24.66

2021-09-24

26.96

2021-09-23

27.07

2021-09-22

26.89

2021-09-21

26.85

2021-09-20

26.48

2021-09-17

27.12

2021-09-16

26.75

2021-09-15

26.39

2021-09-14

26.43

2021-09-13

27.02

2021-09-10

26.53

2021-09-09

27.24

2021-09-08

26.26

2021-09-07

26.53

2021-09-03

26.73

2021-09-02

27.16

2021-09-01

27.16

2021-08-31

27.67

2021-08-30

26.63

2021-08-27

26.77

2021-08-26

26.29

2021-08-25

26.39

2021-08-24

25.99

2021-08-23

25.38

2021-08-20

25.07

2021-08-19

23.37

2021-08-18

24.66

2021-08-17

24.97

2021-08-16

24.92

2021-08-13

26.02

2021-08-12

25.90

2021-08-11

26.02

2021-08-10

25.31

2021-08-09

17.90

2021-08-06

18.09

2021-08-05

18.75

2021-08-04

17.86

2021-08-03

18.21

2021-08-02

18.45

2021-07-30

17.86

2021-07-29

18.22

2021-07-28

18.06

2021-07-27

17.61

2021-07-26

17.71

2021-07-23

17.48

2021-07-22

17.54

2021-07-21

17.70

2021-07-20

17.61

2021-07-19

17.04

2021-07-16

16.75

2021-07-15

17.04

2021-07-14

16.86

2021-07-13

17.58

PS Ratio: 35.26

OMER PS Ratio Chart

OMER Average PS Ratio Chart

OMER Current vs Average PS Ratio Chart

OMER PS Ratio Metrics

OMER Competitors' PS Ratio

P/S vs. estimated history

Sales Valuation

PS Ratio Formula & Definition

PS Ratio FAQ

OMER PS Ratio History

Related Metrics